Industries de la santé

FDA Bill Passes House and Senate: Amendment on Imported Drugs Defeated - Large Contributions from PhRMA & Healthcare Industry to Both Chambers

Imprimer PDF

Écrit par MapLight | 04 Juin 2012

The U.S. House of Representatives passed its version of the FDA user fee bill ( H.R. 5651) Wednesday 387-5. The vote comes on the heels of the Senate’s 96-1 vote passing their version of the bill ( S. 3187) last week. The different bills would need to be reconciled in a conference committee and receive approval from both chambers before receiving President Obama's signature.

Given...

Lire la suite... Ajouter un commentaire

Bacteria Builds Up as Pharmaceutical Progress Lags

Imprimer PDF

Écrit par GBI Research | 29 Mai 2012

NEW YORK (GBI Research), 29 May 2012 - Drug resistance and patent expiries are demanding that the antibacterial drug market moves forwards soon, but a current lack of interest from pharmaceutical companies has led to market stagnation, according to a new report by healthcare experts GBI Research.

The new report* shows that while hospital hygiene campaigns to conquer MRSA encourage...

Lire la suite... Ajouter un commentaire

Clinical Oncology Summit Approaches, Anticipation Mounts!

Imprimer PDF

Écrit par GlobalData | 18 Mai 2012

LONDON, UK (GlobalData), 18 May 2012 - The upcoming American Society of Clinical Oncology (ASCO) meeting is one of the most highly anticipated events in the world of cancer pharmaceuticals. This year’s 48th annual meeting will be held in Chicago from June 1-5, and investors and media outlets are already buzzing. The meeting abstracts released by ASCO on Wednesday, May 16 represent a...

Lire la suite... Ajouter un commentaire

DBV Technologies : Chiffre d'affaires du 1er trimestre, activité scientifique et données cliniques à venir

Imprimer PDF

Écrit par Didier Poli | 15 Mai 2012

Activité R&D accrue avec la préparation du lancement de la Phase IIb

Communication et activité scientifique intense en vue du congrès de l'EAACI

L'AP-HP, partenaire de DBV, présentera lors d'un late breaking abstract : "Six mois d'immunothérapie épicutanée dans l'allergie à l'arachide : innocuité et efficacité"

Nouveau brevet accordé aux Etats-Unis: Viaskin® est désormais le...

Lire la suite... Ajouter un commentaire

Killing Two Birds With One Stone: One Fusion Protein Takes Out Multiple Autoimmune Targets

Imprimer PDF

Écrit par GlobalData | 14 Mai 2012

LONDON, UK (GlobalData), 14 May 2012 - Recently Compugen, Ltd., an Israel-based biopharmaceutical company with over 17 years of research experience, released animal model data from the company’s proprietary Protein Family Members Discovery Platform. This in-house, in silico bioinformatics system provides a predictive view of protein characteristics leading to gene and protein discovery...

Lire la suite... Ajouter un commentaire

Compassionate Use of Pluristem's PLX Cells Saves the Life of a Child after Bone Marrow Transplantation Failure

Imprimer PDF

Écrit par Pluristem | 10 Mai 2012

IM Injections of PLX Cells Causing a Dramatic Recovery of Blood Forming Cells

HAIFA, ISRAEL, May 9, 2012 – Pluristem Therapeutics, Inc. (NASDAQCM:PSTI; TASE:PLTR) today announced that a seven year-old girl suffering from an aplastic bone marrow whose condition was rapidly deteriorating is now experiencing a reversal of her condition with a significant increase in her red cells, white...

Lire la suite... Ajouter un commentaire

Introduction de Vexim sur NYSE Alternext

Imprimer PDF

Écrit par Vexim | 04 Mai 2012

Paris, le 3 mai 2012 - NYSE Euronext annonce aujourd'hui l'introduction de Vexim, un acteur de référence de la microchirurgie innovante du dos, sur NYSE Alternext à Paris.






Fondée en 2006 et basée à Toulouse, Vexim est spécialisée dans le traitement mini-invasif des fractures vertébrales par compression, et a entièrement conçu, développé et commercialisé SpineJack®...

Lire la suite... Ajouter un commentaire

Pluristem Awarded a $3.1 Million Grant by Israeli Government

Imprimer PDF

Écrit par Pluristem | 01 Mai 2012

HAIFA, ISRAEL, April 30, 2012 -- Pluristem Therapeutics Inc. (NasdaqCM:PSTI; TASE: PLTR) today announced that its wholly owned subsidiary, Pluristem Ltd., has received approval for a 11.8 million New Israeli Shekels (approximately $3.1 million) grant from the Office of the Chief Scientist (OCS) within the Israeli Ministry of Industry, Trade and Labor. Once received, the grant will be used...

Lire la suite... Ajouter un commentaire

US Drug Tests Boost Immunochemistry Diagnostics, but Emerging Countries Due to Make Market Takeover

Imprimer PDF

Écrit par GlobalData | 18 Avril 2012

LONDON, UK (GlobalData), 18 April 2012 - China and India are set to dominate the immunochemistry diagnostics market, according to a new report by medical intelligence company GlobalData.

The new report* found that the US presently takes monopoly in the immunochemistry market, largely due to above-average testing for drug abuse. However, emerging countries are anticipated to rise up and...

Lire la suite... Ajouter un commentaire

Plus d'articles...

Information

Annuaires

Vitrines Sociétés

Voir toutes les vitrines